Sign in

    Vikram Paroth

    Research Analyst at Morgan Stanley

    Vikram Purohit is an Analyst at Morgan Stanley specializing in healthcare sector research, covering companies such as Halozyme Therapeutics and Arcutis Biotherapeutics. He has issued 352 price targets and ratings across 25 healthcare stocks, maintaining a track record with an average stock price target met ratio of 46.79% and achieving notable single-stock returns of over 300% on recommendations like Arcutis Biotherapeutics. Purohit’s analysis is recognized by frequent coverage updates and performance metrics, with his career at Morgan Stanley marked by a focus on actionable buy, hold, and sell recommendations in the biotech and pharmaceutical industries. His professional credentials include multiple years of experience as a published healthcare equity analyst, with further details on regulatory licenses not publicly available.

    Vikram Paroth's questions to Kyverna Therapeutics (KYTX) leadership

    Vikram Paroth's questions to Kyverna Therapeutics (KYTX) leadership • Q2 2024

    Question

    Vikram Paroth of Morgan Stanley asked about the timeline for KT474 indication expansion beyond HS and AD, and also inquired about the indication selection strategy for the TIC2 program based on initial Phase 1 data.

    Answer

    President and CEO Nello Manalfi noted broad potential for KT474 in areas like respiratory and GI, but stated Sanofi would determine the timing for expansion. For TIC2, he highlighted its potential to block multiple pathways (IL-23, IL-12, type 1 interferon), with the Phase 1 goal being to demonstrate this differentiated mechanism to inform future indication choices like IBD and psoriasis.

    Ask Fintool Equity Research AI